Advertisement
AXON vs RPRX
Which Stock Would AI Choose? Axon Enterprise, Inc. (AXON) vs. Royalty Pharma plc (RPRX) Stock Comparison
Key Takeaways
- Both AXON and RPRX boast similar market capitalizations around $30 billion and year-to-date (YTD) gains of approximately 29%.
- AXON operates in public safety technology with high growth potential but elevated volatility (beta of 1.43), contrasting RPRX's stable biopharmaceutical royalties business (beta of 0.39).
- AXON trades at a premium trailing price-to-earnings (PE) ratio of about 266, reflecting aggressive growth expectations, while RPRX offers a more reasonable PE of 28 with steady royalty income.
- Recent market activity shows AXON experiencing a pullback from its 52-week highs amid broader sector pressures, while RPRX holds near its peaks with positive analyst updates.
- AXON benefits from AI-driven catalysts in public safety, potentially driving future momentum over RPRX's defensive royalty model.
Introduction
This stock comparison examines AXON and RPRX, two mid-cap leaders with comparable market positioning and YTD performance despite operating in distinct sectors: public safety technology versus biopharmaceutical royalties. Traders seeking growth opportunities with volatility may eye AXON, while those prioritizing stability and income appeal to RPRX. Investors analyzing relative performance, sector exposure, and recent sentiment shifts will find value in understanding their trade-offs in today's market environment.
AXON Overview and Recent Performance
Axon Enterprise, Inc. (AXON) develops public safety technologies, including TASER conducted energy devices, body cameras, and cloud-based software-as-a-service (SaaS) platforms like Axon Evidence and AI-powered tools. The company reported robust revenue growth in recent quarters, with software and services up significantly year-over-year, fueled by expansions in AI applications such as an AI co-pilot for 911 calls. In recent weeks, AXON shares have pulled back from 52-week highs around $886, trading near $402 amid concerns over debt levels and competition in AI stocks, though analysts maintain overweight ratings with targets up to $750. This volatility reflects broader industrial sector dynamics, with a beta of 1.43 indicating heightened sensitivity to market swings.
RPRX Overview and Recent Performance
Royalty Pharma plc (RPRX) is the largest buyer of biopharmaceutical royalties, holding a portfolio of royalties from about 35 marketed therapies and 20 development-stage candidates across areas like oncology and rare diseases. The company generates stable cash flows from sales-based payments, supporting consistent dividends, including a recent $0.235 per share declaration. Shares trade around $49, close to the 52-week high of $50, with low volatility (beta 0.39) and positive sentiment bolstered by UBS raising its price target to $57 while maintaining a buy rating. Recent market activity underscores RPRX's resilience in the healthcare sector, driven by portfolio diversification and R&D funding collaborations.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top 25 AI trading bots from a library of 351, selected for their suitability to current market conditions like volatility in semiconductors, industrials, and ETFs. These bots showcase impressive stats, including annualized returns ranging from 23.53% to 163.10%, win rates of 51.30% to 88.33%, and profit factors up to 11.70, with strategies spanning short-term (15min) to multi-day holds and multi-agent approaches for risk management. Each bot employs unique styles—such as volatility plays on tickers like LRCX or industrials like FIX—tailored to thousands of tickers across sectors. Traders can copy these high-performing signals to align with their risk profiles. Visit the Trending AI Robots page for real-time insights and customization options.
Head-to-Head Comparison
AXON’s hardware-software model drives aggressive expansion in public safety, with projected 27-30% revenue growth contrasting RPRX’s passive royalty streams yielding steady but lower growth. Recent momentum favors RPRX’s stability near highs, while AXON shows pullback risks from high beta and debt/equity of 59% versus RPRX’s 92%. Sector exposure pits AXON’s cyclical industrials against RPRX’s defensive healthcare, with AXON offering higher ROE potential amid AI catalysts but elevated valuation trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently leans toward AXON due to its trend consistency in software growth, emerging AI catalysts in public safety, and relative positioning for upside despite recent volatility, over RPRX’s steadier but less dynamic profile. This probabilistic edge reflects observable momentum factors in recent market activity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and RPRX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileRPRX’s FA Score has 2 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- RPRX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 5 TA indicator(s) are bullish while RPRX’s TA Score has 4 bullish TA indicator(s).
- AXON’s TA Score: 5 bullish, 3 bearish.
- RPRX’s TA Score: 4 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -2.89% price change this week, while RPRX (@Biotechnology) price change was +4.52% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -2.02%. For the same industry, the average monthly price growth was -3.16%, and the average quarterly price growth was +45.17%.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.25%. For the same industry, the average monthly price growth was -2.77%, and the average quarterly price growth was +7.50%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
RPRX is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Aerospace & Defense (-2.02% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-2.25% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | RPRX | AXON / RPRX | |
| Capitalization | 31.6B | 23.4B | 135% |
| EBITDA | 320M | 1.7B | 19% |
| Gain YTD | -30.999 | 38.099 | -81% |
| P/E Ratio | 158.02 | 27.82 | 568% |
| Revenue | 2.98B | 2.44B | 122% |
| Total Cash | 737M | N/A | - |
| Total Debt | 1.83B | 8.95B | 20% |
AXON | RPRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 77 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 2 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 52 | |
SMR RATING 1..100 | 80 | 95 | |
PRICE GROWTH RATING 1..100 | 64 | 41 | |
P/E GROWTH RATING 1..100 | 60 | 9 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RPRX's Valuation (2) in the Pharmaceuticals Major industry is significantly better than the same rating for AXON (82) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than AXON’s over the last 12 months.
RPRX's Profit vs Risk Rating (52) in the Pharmaceuticals Major industry is in the same range as AXON (72) in the Biotechnology industry. This means that RPRX’s stock grew similarly to AXON’s over the last 12 months.
AXON's SMR Rating (80) in the Biotechnology industry is in the same range as RPRX (95) in the Pharmaceuticals Major industry. This means that AXON’s stock grew similarly to RPRX’s over the last 12 months.
RPRX's Price Growth Rating (41) in the Pharmaceuticals Major industry is in the same range as AXON (64) in the Biotechnology industry. This means that RPRX’s stock grew similarly to AXON’s over the last 12 months.
RPRX's P/E Growth Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for AXON (60) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than AXON’s over the last 12 months.
| AXON | RPRX | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 81% | 3 days ago 44% |
| Stochastic ODDS (%) | 3 days ago 78% | 3 days ago 57% |
| Momentum ODDS (%) | 3 days ago 68% | 3 days ago 48% |
| MACD ODDS (%) | 3 days ago 71% | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 67% | 3 days ago 52% |
| TrendMonth ODDS (%) | 3 days ago 70% | 3 days ago 54% |
| Advances ODDS (%) | 3 days ago 74% | 4 days ago 54% |
| Declines ODDS (%) | 5 days ago 69% | 19 days ago 54% |
| BollingerBands ODDS (%) | 3 days ago 60% | 3 days ago 55% |
| Aroon ODDS (%) | 3 days ago 73% | 3 days ago 67% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ASTX | 31.43 | 0.44 | +1.42% |
| Tradr 2X Long ASTS Daily ETF | |||
| ACSV | 46.06 | N/A | N/A |
| American Century Small Cp Val Insgts ETF | |||
| USCI | 101.18 | -0.20 | -0.20% |
| United States Commodity Index | |||
| DVYA | 50.92 | -0.33 | -0.64% |
| iShares Asia/Pacific Dividend ETF | |||
| JPC | 7.78 | -0.11 | -1.36% |
| Nuveen Preferred & Income Opportunities Fund | |||
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | +0.95% | ||
| TECH - AXON | 61% Loosely correlated | -3.22% | ||
| VCYT - AXON | 58% Loosely correlated | -1.08% | ||
| BEAM - AXON | 57% Loosely correlated | -5.42% | ||
| SEER - AXON | 56% Loosely correlated | -1.71% | ||
| ADPT - AXON | 56% Loosely correlated | -2.66% | ||
More | ||||
RPRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To RPRX | 1D Price Change % | ||
|---|---|---|---|---|
| RPRX | 100% | -0.59% | ||
| AXON - RPRX | 48% Loosely correlated | +0.95% | ||
| MDGL - RPRX | 31% Poorly correlated | -3.00% | ||
| INCY - RPRX | 31% Poorly correlated | -2.38% | ||
| ARRY - RPRX | 30% Poorly correlated | +4.06% | ||
| HALO - RPRX | 30% Poorly correlated | -3.02% | ||
More | ||||